Navigation Links
Modified Drug Therapy for Alzheimers Disease

Purdue university researchers has found a new modified drug for Alzheimers disease.The drug has begun the first phase of clinical trials.

Millions of people suffer from this devastating disease and treatment options are very limited," said Arun Ghosh, the Purdue professor who led the creation of the treatment molecule. "Current drugs manage the symptoms, but this could be the first disease-modifying therapy. It may be able to prevent and reverse the disease."

CoMentis Inc., a biopharmaceutical company based in San Francisco, is initiating the clinical trials of the experimental drug CTS-21166. Ghosh, who has dual appointments in the departments of chemistry and medicinal chemistry, is a scientific co-founder of the company with Jordan Tang, the J.G. Puterbaugh Chair in Medical Research at the Oklahoma Medical Research Foundation.

The collaborative work of Ghosh and Tang led to the development of a treatment that could intercept and disable the disease at an early stage.In 2000, Tang identified beta-secretase, a key enzyme in the progression of Alzheimer's that triggers the formation of amyloid plaques in the brain.

Various stages in plaque formation produce toxic proteins that harm the brain, causing damage that eventually leads to dementia. Later that year, Ghosh built a molecule that binds to this key enzyme and inhibits its activity, a beta-secretase inhibitor.

X-ray crystal structureDownload photo caption below These molecules fit together like puzzle pieces," Ghosh said. "We created a molecule that fits with a key piece of the Alzheimer's disease puzzle. When the treatment molecule binds to the enzyme, it changes the shape of that puzzle piece so that it no longer fits in its original spot. This halts the chain reaction that leads to the devastating symptoms of Alzheimer's disease."

Since 2000, Ghosh has been leading the structure-based design of beta-secreatase inhibitors f or therapeutic intervention of Alzheimer's disease. His most recent work was published in the May 17 issue of the Journal of Medicinal Chemistry.

Ghosh also helped direct CoMentis in the generation of beta-secretase inhibitor drugs. The treatment molecule, beta-secretase inhibitor CTS-21166, is the culmination of this work.

"The molecule is both highly potent and highly selective, meaning it does not appear to affect other enzymes important to brain function or cause harmful side effects," Ghosh said. "It took years of work and evaluation of hundreds of molecules to achieve one with the strength and safety necessary for clinical potential."

The trial, comprised of 48 healthy volunteers, will measure safety, tolerability and pharmacokinetics of CTS-21166 at various doses. The company expects to begin generating human clinical data by the end of 2007 and to begin phase II studies in Alzheimer's patients in 2008. The drug could be administered at any stage of the disease, Ghosh said.

These clinical trial phases are the first steps in a lengthy process necessary before the Food and Drug Administration approves a drug to be available on the market.




'"/>




Related medicine news :

1. Modified antibiotic may support fight cancer
2. Malaria To Be Tackled By Genetically Modified Mosquitoes
3. Stroke Rehabilitation Through Modified Video Games
4. Genetically Modified Cells Attack Tumors
5. TB can Be Eradicated in the U.S With Modified Guidelines: Study
6. Modified Ligament Surgery Improves Outcomes Players, Athletes
7. Cancer Doctors Okays Controversial Prostate Therapy
8. Consensus on "Combination Therapy" for Breast Cancer
9. Gene Therapy shows promise in treating Hemophilia
10. "Make AIDS Therapy affordable" - Physicians demand
11. Hormone replacement Therapy a headache
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/22/2017)... ... ... “To Walk Away”: a captivating and romantic sequel to the romantic story ... is the creation of published author, Larry R. Sherman, a retired chemistry professor from ... religion, as well as four novels. , Though the book opens in 1947, ...
(Date:8/22/2017)... ... August 22, 2017 , ... “Without Love’s Beauty ... neglect, and the struggles faced while hoping for a better life. “Without Love’s ... Judy Von Bernewitz, who spent 13 years working with deprived/neglected adolescents and almost ...
(Date:8/22/2017)... ... August 22, 2017 , ... “Glimpses Of Light”: is a ... “Glimpses Of Light” is the creation of published author, J.M. Shepherd, a writer, teacher, ... answers to life’s perplexing mysteries. , Shepherd shares, “Love is one of the least ...
(Date:8/22/2017)... ... August 22, 2017 , ... TopConsumerReviews.com recently gave a best-in-class ... Fatigue . , As the stress of modern life continually makes more demands on ... use of artificial stimulants can trap people in vicious high/low cycles and can also ...
(Date:8/22/2017)... Indiana (PRWEB) , ... August 22, 2017 , ... Although ... Fourth of July, many communities have begun providing weekend displays, and numerous households celebrate ... most humans, they can be downright terrifying for pets. , Kris Zambo, owner ...
Breaking Medicine News(10 mins):
(Date:8/2/2017)... and BENTON, Ky. , Aug. 2, 2017   Marshall County Hospital ... environmental services (ES) team to proactively reduce the risk of hospital-acquired infections (HAIs). The new ... robot that uses UVC light energy to kill deadly pathogens such as C. diff ... Tru-D SmartUVC ... Tru-D in action in a ...
(Date:7/31/2017)... July 31, 2017  Diplomat Pharmacy, Inc. (NYSE: DPLO), has ... Michigan by Crain,s Detroit Business . ... public companies by three-year revenue growth. This year,s edition measures ... To view the complete list, visit crainsdetroit.com/awards/fast_50/2017 .  ... an incredible triumph," said Phil Hagerman , CEO and ...
(Date:7/28/2017)... July 28, 2017 EnvoyHealth, a Diplomat company, has ... program for CleverCap LITE, a technology designed to improve ... deliver innovative health technology solutions and services that help ... CleverCap LITE offers medication monitoring and ... cover: Records date ...
Breaking Medicine Technology: